Dubrocq Gueorgui, Rakhmanina Natella, Phelps B Ryan
Division of Pediatric Infectious Diseases, Children's National Health System, 111 Michigan Ave NW, Washington, 20310, DC, USA.
Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Paediatr Drugs. 2017 Apr;19(2):91-98. doi: 10.1007/s40272-016-0210-4.
Successful management of pediatric HIV disease requires high therapeutic efficacy and adherence, which can be achieved by providing affordable, easy to store, and palatable antiretrovirals. Current challenges in pediatric antiretroviral drug development include poor palatability, large pill size, limited oral liquid formulations, and few incentives for development by drug manufacturers as the number of children with HIV continues to decline due to successful worldwide preventive interventions and improved access to antiretrovirals. This article summarizes the various challenges and opportunities with current pediatric antiretrovirals, recent and ongoing trials, new formulations, and suggestions that may expedite and provide incentives for the development of suitable pediatric formulations.
成功管理儿童HIV疾病需要高治疗效果和依从性,这可以通过提供价格可承受、易于储存且口感良好的抗逆转录病毒药物来实现。儿童抗逆转录病毒药物开发目前面临的挑战包括口感差、药片尺寸大、口服液体制剂有限,以及由于全球预防干预措施的成功和抗逆转录病毒药物可及性的改善,感染HIV的儿童数量持续下降,药物制造商缺乏开发动力。本文总结了当前儿童抗逆转录病毒药物面临的各种挑战和机遇、近期及正在进行的试验、新剂型,以及可能加快并为开发合适儿童剂型提供动力的建议。